欧米茄-3脂肪酸,氨酸或其他营养补充剂对认知功能的影响:AREDS2随机临床试验
Emily Y Chew1, Traci E Clemons2, Elvira Agrón1
1Division of Epidemiology and Clinical Applications, Clinical Trials Branch, National Eye Institute/National Institutes of Health, Bethesda, Maryland.
JAMA
|August 26, 2015
概括
长链多不和脂肪酸 (LCPUFA) 或黄蛋白/ 泽亚桑丁的口服补充剂对与年龄相关的黄斑变性 (AMD) 患者的认知功能没有显著影响. 这项研究没有发现这些营养干预对认知表现有好处.
科学领域:
- 营养神经科学
- 眼科 眼科
- 老年学
背景情况:
- 观察性研究表明饮食 (高和脂肪,低蔬菜) 与阿尔茨海默病风险之间存在联系.
- 年龄相关眼病研究2 (AREDS2) 调查了与年龄相关的黄斑变性 (AMD) 的营养补充.
- 在AREDS2的辅助研究中,研究了特定营养素对认知功能的影响.
研究的目的:
- 评估口服补充长链多不和脂肪酸 (LCPUFA) 和/或氨酸/氨酸对认知功能的有效性.
- 确定这些营养素与其他维生素和矿物质结合, 影响老年人的认知能力.
主要方法:
- 一个双面罩的随机临床试验, 涉及晚期AMD风险的参与者.
- 参与者在因子设计中接受LCPUFAs (1 g) 和/或氨酸 (10 mg) / zeaxanthin (2 mg) 或安慰剂.
- 认知功能在基线和五年内每两年进行一次通过电话进行的验证测试.
主要成果:
- 在补充剂和安慰剂组之间没有观察到认知功能得分的统计学意义上的差异.
- 综合认知评分的年度变化在LCPUFA或氨酸/ 泽亚桑丁补充剂中没有显著差异.
- 对于认知结果,没有发现LCPUFAs与黄蛋白/ 泽亚桑丁补充剂之间的显著相互作用.
结论:
- 在老年 AMD 患者中,口服 LCPUFAs 或氨酸/ 泽亚桑丁的补充并没有对认知功能产生显著的改善.
- 这些发现表明,在测试条件下,LCPUFAs和氨酸/氨酸对增强这一群体的认知功能无效.
相关概念视频
01:26Atherosclerosis III: Management
589
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
589
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
856
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
856
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K